The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Reporting bias in medical research - a narrative review
Open accessAbstract
Reporting bias represents a major problem in the assessment of health care interventions. Several prominent cases have been described in the literature, for example, in the reporting of trials of antidepressants, Class I anti-arrhythmic drugs, and selective COX-2 inhibitors. The aim of this narrative review is to gain an overview of reporting bias in the medical literature, focussing on publication bias and selective outcome reporting. We explore whether these types of bias have been shown in areas beyond the well-known cases noted above, in order to gain an impression of how widespread the problem is. For this purpose, we screened relevant articles on reporting bias that had previously been obtained by the German Institute for Quality and Efficiency in Health Care in the context of its health technology assessment reports and other research work, together with the reference lists of these articles.We identified reporting bias in 40 indications comprising around 50 different pharmacological, surgical (e.g. vacuum-assisted closure therapy), diagnostic (e.g. ultrasound), and preventive (e.g. cancer vaccines) interventions. Regarding pharmacological interventions, cases of reporting bias were, for example, identified in the treatment of the following conditions: depression, bipolar disorder, schizophrenia, anxiety disorder, attention-deficit hyperactivity disorder, Alzheimer's disease, pain, migraine, cardiovascular disease, gastric ulcers, irritable bowel syndrome, urinary incontinence, atopic dermatitis, diabetes mellitus type 2, hypercholesterolaemia, thyroid disorders, menopausal symptoms, various types of cancer (e.g. ovarian cancer and melanoma), various types of infections (e.g. HIV, influenza and Hepatitis B), and acute trauma. Many cases involved the withholding of study data by manufacturers and regulatory agencies or the active attempt by manufacturers to suppress publication. The ascertained effects of reporting bias included the overestimation of efficacy and the underestimation of safety risks of interventions.In conclusion, reporting bias is a widespread phenomenon in the medical literature. Mandatory prospective registration of trials and public access to study data via results databases need to be introduced on a worldwide scale. This will allow for an independent review of research data, help fulfil ethical obligations towards patients, and ensure a basis for fully-informed decision making in the health care system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, the medical literature represents a biased subset of existing data, potentially leading to overestimation of benefits, underestimation of harms, and a detrimental impact on patient care and research.112 117 118”
From SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials (2025) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–223 of 223
FDA warns that antidepressants may increase suicidality in adults
Lenzer, J. (2005) · BMJ · doi:10.1136/bmj.331.7508.70-b · Cited by 14
Ethics in Science: Is Data-Hoarding Slowing the Assault on Pathogens?
Marshall, E. (1997) · Science · doi:10.1126/science.275.5301.777 · Cited by 13
[Constraints on publication rights in industry-initiated clinical trials--secondary publication].
Gøtzsche, P. C., Hróbjartsson, A., Johansen, H. K., Haahr, M. T., Altman, D. G., & Chan, A. (2006) · PubMed · Cited by 13
Research suppressed for seven years by drug company
Wise, J. (1997) · BMJ · doi:10.1136/bmj.314.7088.1145 · Cited by 12
Bayer faces potential fine over cholesterol lowering drug
Tuffs, A. (2001) · BMJ · doi:10.1136/bmj.323.7310.415a · Cited by 12
Zinberg, D. S. (1996) · Science · doi:10.1126/science.273.5274.411 · Cited by 12
Making information about clinical trials publicly available
Smyth, R. L. (2009) · BMJ · doi:10.1136/bmj.b2473 · Cited by 9
Bayer withdraws heart surgery drug
Tuffs, A. (2007) · BMJ · doi:10.1136/bmj.39395.644826.db · Cited by 8
Alosetron for irritable bowel syndrome
Barbehenn, E. K., Lurie, P. G., & Wolfe, S. M. (2000) · The Lancet · doi:10.1016/s0140-6736(05)72978-0 · Cited by 7
Unreported cholesterol drug data released by company
Lenzer, J. (2008) · BMJ · doi:10.1136/bmj.39468.610775.db · Cited by 6
German agency refuses to rule on drug's benefits until Pfizer discloses all trial results
Stafford, N. (2009) · BMJ · doi:10.1136/bmj.b2521 · Cited by 6
When Evidence Isn't: Trials, Drug Companies and the FDA
Rennie, D. (2008) · bepress Legal Repository · Cited by 6
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
WHO clinical trials initiative to protect the public.
(2006) · Europe PMC (PubMed Central) · Cited by 5
Merck defends Vioxx in court, as publisher apologises for fake journal
Moynihan, R. N. (2009) · BMJ · doi:10.1136/bmj.b1914 · Cited by 4
The Rosigliazone Meta-Analysis
Shuster, J. J., & Schatz, D. (2008) · Diabetes Care · doi:10.2337/dc07-2147 · Cited by 4
Commentary: Publishing Cancer Clinical Trial Results: A Scientific and Ethical Imperative
Doroshow, J. H. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0168 · Cited by 4
Completeness of Safety Reporting in Randomized Trials: An Evaluation of 7 Medical Areas
Ioannidis, J. P. A., & Lau, J. (2001) · JAMA · doi:10.1001/jama.285.4.437 · Cited by 3
SULLIVAN, M. G. (2005) · Skin & Allergy News · doi:10.1016/s0037-6337(05)70192-3 · Cited by 3
US consumer groups allege misleading drug claims
Gottlieb, S. (2001) · BMJ · doi:10.1136/bmj.323.7310.415 · Cited by 3
Merck to pay $58m in settlement over rofecoxib advertising
Charatan, F. B. (2008) · BMJ · doi:10.1136/bmj.39591.705231.db · Cited by 3
[Fatal medicine. Unpublished studies--harmless?].
Antes, G. (2006) · PubMed · doi:10.1007/bf03364797 · Cited by 2
Research works printed but not linked: 17
- National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal. London. 2008
- Moore TJ: Deadly medicine: why tens of thousands of heart patients died in America's worst drug disaster. 1995, New York: Simon & Schuster
- Mathews A, Martinez B: E-mails suggest Merck knew Vioxx's dangers at early stage. Wall Street Journal. 2004, A1-
- Vedantam S: A silenced drug study creates an uproar. Washington Post. 2009, A01-
- Lurie P, Zieve A: Sometimes the silence can be like the thunder: access to pharmaceutical data at the FDA. Law Contemp Probl. 2008, 69: 85-97.
- King RT: Bitter pill: how a drug firm paid for university study, then undermined it. Wall Street Journal. 1996, 1: A13-
- Hilts PJ: Philip Morris blocked paper showing addiction, panel finds. New York Times. 1994, A7-
- Hilts PJ: Scientists say Philip Morris withheld nicotine findings. New York Times. 1994, A1-A7.
- Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) no 1768/92, directive 2001/20/EC, directive 2001/83/EC and regulation (EC) No 726/2004. Official J Eur Commun. 2006, 49: L378/1-L378/19.
- Verband Forschender Arzneimittelhersteller: VFA-Positionspapier zum Thema "publication bias" [VFA position paper on the subject of "publication bias"]. 2008, Berlin: VFA
- Petersen M: Memos cast shadow on drug's promotion. New York Times. 2002, C2-
- Waxman HA: The Marketing of Vioxx to Physicians (Memorandum to Democratic members of the Government Reform Committee). 2005
- West RR, Jones DA: Publication bias in statistical overview of trials: example of psychological rehabilitation following myocardial infarction [Abstract]. Proceedings of the 2nd International Conference on the Scientific Basis of Health Services and 5th Annual Cochrane Colloquium; 1997 Oct 8-12; Amsterdam. Amsterdam. 1999, 17-
- Lenzer J: Drug secrets: what the FDA isn't telling. Slate Magazine. 2005, http://www.slate.com/id/2126918
- Berenson A: Data about Zetia risks was not fully revealed. New York Times. 2007
- Harris G: Approval of antibiotic worried safety officials. New York Times. 2006
- Blumsohn A: Authorship, ghostscience, access to data and control of the pharmaceutical scientific literature: who stands behind the word?. Prof Ethics Rep. 2006, 19: 1-4.
Cited by
Sorted by citations
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Suñé, P., Suñé, J. M., & Montoro, J. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054583 · Cited by 1,687
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Progress in evidence-based medicine: a quarter century on
Djulbegovic, B., & Guyatt, G. H. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31592-6 · Cited by 1,022
Increasing value and reducing waste: addressing inaccessible research
Chan, A.-W., Song, F., Vickers, A., Jefferson, T., Dickersin, K., Gøtzsche, P. C., Krumholz, H. M., Ghersi, D., & van der Worp, H. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62296-5 · Cited by 887
Metadata
- Authors
- McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T.
- Affiliations
- Institute for Quality and Efficiency in Health Care (DE)
- Corresponding author
- McGauran, Natalie
- Venue
- Trials
- Published
- 2010-04-13
- Volume
- 11
- Issue
- 1
- Pages
- 37-37
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC2867979
- OpenAlex
- W2130998313
- Cited by
- 452
- References
- 223
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 15 · 2023: 29 · 2022: 23 · 2021: 31 · 2020: 40 · 2019: 28 · 2018: 38 · 2017: 26 · 2016: 26 · 2015: 33 · 2014: 24 · 2013: 35 · 2012: 35
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Trials (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- reporting bias, publication bias, selective outcome reporting
- MeSH terms
- Animals, Consumer Product Safety, Humans, Periodicals as Topic, Registries, Truth Disclosure, Reproducibility of Results, Treatment Outcome, Publication Bias, Evidence-Based Medicine, Databases as Topic, Access to Information, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review